Teva's Stock Declines Amid Broader Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Source: Benzinga
Teva Pharmaceutical Industries Limited's stock fell 4.56% and hit a 20-day low, reflecting broader market trends as the Nasdaq-100 and S&P 500 both experienced declines.
Despite the stock's decline, Teva's recent settlement with UroGen Pharma over the patent dispute regarding the cancer therapy Jelmyto may provide a new revenue stream through a non-exclusive license for its generic version starting in 2030. This settlement reduces future legal risks and enhances Teva's competitiveness in the generic drug market.
The implications of this settlement could be significant for Teva, as it not only secures a future revenue source but also demonstrates the company's proactive approach in navigating legal challenges while expanding its product offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.560
Low
29.00
Averages
35.71
High
40.00
Current: 32.560
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceuticals to Release Q2 2026 Financial Results
- Earnings Release Schedule: Teva Pharmaceuticals plans to announce its Q2 2026 financial results on July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET to discuss financial performance and future outlook.
- Participation Instructions: Investors must register in advance to obtain a local or toll-free phone number and personal PIN to ensure smooth access to the call and relevant information.
- Webcast Availability: The conference call will be available via live webcast on Teva's website, and a replay will be accessible within 24 hours post-call, allowing investors who cannot attend live to catch up on the discussion.
- Strategic Transformation: Teva is transforming into a leading innovative biopharmaceutical company, leveraging its world-class generics business to meet patient health needs while showcasing its innovation capabilities in neuroscience and immunology.
See More
Teva Seeks FDA Approval for Ecopipam in Pediatric Tourette Syndrome
- NDA Submission: Teva Pharmaceutical has submitted an NDA to the US FDA for ecopipam, aiming for approval in treating pediatric Tourette syndrome, marking a strategic expansion into the neuropsychiatric domain.
- Clinical Data Support: The application is backed by phase 3 trial data, which demonstrated that ecopipam significantly delayed time to relapse during an open-label treatment period compared to the placebo group, indicating superior efficacy.
- Sustained Efficacy: Over a treatment duration of up to 24 weeks, ecopipam achieved a meaningful and sustained reduction in the severity of tics, suggesting potential long-term benefits for pediatric patients.
- First-in-Class Drug: Ecopipam is considered a first-in-class medication that inhibits dopamine signaling at the D1 receptor, potentially offering new treatment options in the field and enhancing Teva's competitive position in the market.
See More
Teva Pharmaceuticals Releases Q2 2026 Aide Memoire
- Aide Memoire Release: Teva Pharmaceuticals announced on June 18, 2026, that its Q2 2026 Aide Memoire is now available on the 'Investors' page of its website, aimed at assisting investors ahead of the upcoming earnings report scheduled for July 29, 2026.
- Earnings Report Schedule: The company plans to release its Q2 earnings at 7:00 a.m. ET on July 29, 2026, followed by a conference call at 8:00 a.m. ET, ensuring that investors receive timely updates on the company's performance.
- Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, leveraging its world-class generics business to innovate in neuroscience and immunology while providing complex generics and biosimilars to meet global patient needs.
- Cautionary Forward-Looking Statements: The Aide Memoire includes forward-looking statements that caution investors about potential risks affecting future performance, such as market competition, significant debt levels, and compliance issues, highlighting the company's commitment to transparency and risk management.
See More
Teva Submits NDA for Ecopipam to Treat Pediatric Tourette Syndrome
- NDA Milestone: Teva Pharmaceutical Industries has submitted a New Drug Application (NDA) to the FDA for ecopipam, marking a significant step in pediatric Tourette syndrome treatment, potentially becoming the first FDA-approved option in over a decade if approved.
- Clinical Data Support: The NDA is backed by positive Phase 3 trial data recently published in JAMA Neurology, demonstrating that ecopipam significantly delayed time to relapse compared to placebo (p = 0.008), providing strong evidence for its market potential.
- Adverse Event Management: In the Phase 3 study, ecopipam was generally well tolerated, with common adverse events including somnolence (11.1%), anxiety (9.7%), and headache (9.7%), indicating good safety in clinical use, which may attract more patients.
- Strategic Transformation Opportunity: This NDA submission aligns with Teva's
See More
Medincell SA Reports Growth Strategy Success with Strong Financials
- Successful Growth Strategy: Medincell SA has effectively executed its Shift to Growth strategy, with strong performance across its three growth engines, particularly Risperidone LAI and Holonza PIN LAI, demonstrating the company's competitiveness in the mental health drug market.
- Significant Sales Increase: Teva's net sales reached $215 million, up from $141 million last year, reflecting robust market demand for the company's products, which will help enhance overall revenue.
- Strong Financial Position: The company maintains a cash reserve of €85 million, ensuring long-term financial visibility and flexibility to support future growth strategies, despite an increase in operating expenses.
- Pipeline Expansion: Medincell is actively expanding its pipeline with 15 active programs at the formulation stage, focusing on high-value indications, indicating the company's commitment to capturing future market opportunities.
See More
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
- Stock Price Recovery: Teva Pharmaceutical's stock has surged by 97% over the past year, indicating a significant recovery from previous challenges including debt and litigation, although the current price may not present an ideal buying opportunity.
- Biosimilars Market: Teva has launched two biosimilars in partnership with Alvotech, namely Simlandi in May 2024 and Selarsdi in February 2025, with expectations for its biosimilars business to double to around $800 million by 2027, despite facing fierce competition and narrow profit margins.
- Branded Drug Performance: The company's resurgence is primarily driven by its branded drugs, particularly Austedo, which achieved approximately $2.3 billion in sales in 2025, highlighting strong demand in treating movement disorders, although overall revenue is projected to be flat or decline in 2026.
- Investor Caution: Despite the evident recovery, Teva's current P/E ratio of about 25 suggests that its valuation is no longer attractive, prompting investors to carefully assess future growth potential, especially as better investment opportunities may exist in other areas of the pharmaceutical industry.
See More
Teva Pharmaceuticals to Release Q2 2026 Financial Results
- Earnings Release Schedule: Teva Pharmaceuticals plans to announce its Q2 2026 financial results on July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET to discuss financial performance and future outlook.
- Participation Instructions: Investors must register in advance to obtain a local or toll-free phone number and personal PIN to ensure smooth access to the call and relevant information.
- Webcast Availability: The conference call will be available via live webcast on Teva's website, and a replay will be accessible within 24 hours post-call, allowing investors who cannot attend live to catch up on the discussion.
- Strategic Transformation: Teva is transforming into a leading innovative biopharmaceutical company, leveraging its world-class generics business to meet patient health needs while showcasing its innovation capabilities in neuroscience and immunology.
See More
Teva Seeks FDA Approval for Ecopipam in Pediatric Tourette Syndrome
- NDA Submission: Teva Pharmaceutical has submitted an NDA to the US FDA for ecopipam, aiming for approval in treating pediatric Tourette syndrome, marking a strategic expansion into the neuropsychiatric domain.
- Clinical Data Support: The application is backed by phase 3 trial data, which demonstrated that ecopipam significantly delayed time to relapse during an open-label treatment period compared to the placebo group, indicating superior efficacy.
- Sustained Efficacy: Over a treatment duration of up to 24 weeks, ecopipam achieved a meaningful and sustained reduction in the severity of tics, suggesting potential long-term benefits for pediatric patients.
- First-in-Class Drug: Ecopipam is considered a first-in-class medication that inhibits dopamine signaling at the D1 receptor, potentially offering new treatment options in the field and enhancing Teva's competitive position in the market.
See More
Teva Pharmaceuticals Releases Q2 2026 Aide Memoire
- Aide Memoire Release: Teva Pharmaceuticals announced on June 18, 2026, that its Q2 2026 Aide Memoire is now available on the 'Investors' page of its website, aimed at assisting investors ahead of the upcoming earnings report scheduled for July 29, 2026.
- Earnings Report Schedule: The company plans to release its Q2 earnings at 7:00 a.m. ET on July 29, 2026, followed by a conference call at 8:00 a.m. ET, ensuring that investors receive timely updates on the company's performance.
- Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, leveraging its world-class generics business to innovate in neuroscience and immunology while providing complex generics and biosimilars to meet global patient needs.
- Cautionary Forward-Looking Statements: The Aide Memoire includes forward-looking statements that caution investors about potential risks affecting future performance, such as market competition, significant debt levels, and compliance issues, highlighting the company's commitment to transparency and risk management.
See More
Teva Submits NDA for Ecopipam to Treat Pediatric Tourette Syndrome
- NDA Milestone: Teva Pharmaceutical Industries has submitted a New Drug Application (NDA) to the FDA for ecopipam, marking a significant step in pediatric Tourette syndrome treatment, potentially becoming the first FDA-approved option in over a decade if approved.
- Clinical Data Support: The NDA is backed by positive Phase 3 trial data recently published in JAMA Neurology, demonstrating that ecopipam significantly delayed time to relapse compared to placebo (p = 0.008), providing strong evidence for its market potential.
- Adverse Event Management: In the Phase 3 study, ecopipam was generally well tolerated, with common adverse events including somnolence (11.1%), anxiety (9.7%), and headache (9.7%), indicating good safety in clinical use, which may attract more patients.
- Strategic Transformation Opportunity: This NDA submission aligns with Teva's
See More
Medincell SA Reports Growth Strategy Success with Strong Financials
- Successful Growth Strategy: Medincell SA has effectively executed its Shift to Growth strategy, with strong performance across its three growth engines, particularly Risperidone LAI and Holonza PIN LAI, demonstrating the company's competitiveness in the mental health drug market.
- Significant Sales Increase: Teva's net sales reached $215 million, up from $141 million last year, reflecting robust market demand for the company's products, which will help enhance overall revenue.
- Strong Financial Position: The company maintains a cash reserve of €85 million, ensuring long-term financial visibility and flexibility to support future growth strategies, despite an increase in operating expenses.
- Pipeline Expansion: Medincell is actively expanding its pipeline with 15 active programs at the formulation stage, focusing on high-value indications, indicating the company's commitment to capturing future market opportunities.
See More
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
- Stock Price Recovery: Teva Pharmaceutical's stock has surged by 97% over the past year, indicating a significant recovery from previous challenges including debt and litigation, although the current price may not present an ideal buying opportunity.
- Biosimilars Market: Teva has launched two biosimilars in partnership with Alvotech, namely Simlandi in May 2024 and Selarsdi in February 2025, with expectations for its biosimilars business to double to around $800 million by 2027, despite facing fierce competition and narrow profit margins.
- Branded Drug Performance: The company's resurgence is primarily driven by its branded drugs, particularly Austedo, which achieved approximately $2.3 billion in sales in 2025, highlighting strong demand in treating movement disorders, although overall revenue is projected to be flat or decline in 2026.
- Investor Caution: Despite the evident recovery, Teva's current P/E ratio of about 25 suggests that its valuation is no longer attractive, prompting investors to carefully assess future growth potential, especially as better investment opportunities may exist in other areas of the pharmaceutical industry.
See More
